Surface oncology, inc. (SURF)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16
Cash flows from operating activities:
Net income (loss)

-54,789

-6,597

-45,377

-17,453

Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization expense

1,785

1,347

964

331

Stock-based compensation expense

5,991

5,217

4,709

1,345

Non-cash interest expense related to note payable

74

-

-

-

Premiums paid on marketable securities

-

-

-

1,841

Net amortization of premiums and discounts on marketable securities

764

377

-516

-477

Realized losses on marketable securities

-

-

-2

13

Loss on disposal of property and equipment

-1

-14

-35

0

Non-cash operating lease cost

1,814

-

-

-

Changes in operating assets and liabilities:
Amounts due from related party

-

-

-5,000

5,000

Prepaid expenses and other current assets

-3,001

-2,170

-1,088

8,549

Other assets

-12

26

12

-41

Accounts payable

583

23

285

1,800

Accrued expenses and other current liabilities

-710

-524

2,945

5,430

Deferred rent

-

52

-249

86

Operating lease liability

-1,778

-

-

-

Deferred revenue - related party

-15,360

-14,417

17,174

64,931

Net cash used in operating activities

-60,140

-13,222

-12,422

41,413

Purchases of property and equipment

1,538

2,019

1,973

836

Purchases of marketable investments

118,347

107,257

-

97,048

Proceeds from sales or maturities of marketable securities

136,850

72,692

27,891

28,916

Net cash provided by (used in) investing activities

16,965

-36,584

25,918

-68,968

Cash flows from financing activities:
Proceeds from issuances of redeemable convertible preferred stock, net of issuance costs

-

-

-

25,938

Payments of initial public offering costs

-

2,031

1,200

-

Proceeds from issuance of common stock upon public offering, net

-

100,440

-

-

Proceeds from issuance of common stock to a related party

-

11,500

-

-

Collection of note receivable from officer

-

-

62

-

Proceeds from issuance of convertible note payable, net of issuance costs

7,217

-

-

-

Payments of debt issuance costs

81

-

-

-

Proceeds for issuance of common stock offering, net

24

-

-

-

Proceeds from exercise of stock options

255

467

102

4

Net cash provided by financing activities

7,415

110,376

-1,036

25,942

Net increase (decrease) in cash and cash equivalents and restricted cash

-35,760

60,570

12,460

-1,613

Supplemental disclosure of cash flow information:
Cash paid for income taxes

-

28

3,297

7,673

Supplemental disclosure of non-cash investing and financing activities:
Accretion of redeemable convertible preferred stock to redemption value

-

11

40

41

Purchases of property and equipment included in accounts payable and accrued expenses

-

692

450

352

Deferred offering costs included in accrued expenses

-

-

584

-

Reclassification of restricted cash from non-current assets to current assets

-

-

85

-

Reclassification of deposit liability for restricted stock upon vesting of shares

-

-

35

26

Landlord incentives for construction of leasehold improvements recorded as deferred rent

-

-

2,377

2,426